Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Investor Presentation (November 2023)
12 slides from Avecho Biotechnology's investor presentation, Nov 9, 2023
Slide 1: Avecho Biotechnology November 2023
NOVEMBER 2023 For personal use only www.avecho.com.au | ASX:AVE
Slide 2: Safe Harbour Statement
SAFE HARBOUR STATEMENT AVECHO BIOTECHNOLOGY For personal use only This presentation, and any representations made before, during or after the presentation, may include forward- looking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not limited
Slide 3: Clear Strategic Focus
CLEAR STRATEGIC FOCUS For personal use only 1. Complete pivotal Phase III clinical trial for CBD capsule containing TPM® technology 2. License this and other TPM cannabinoid products into lucrative global markets May 2022 3 AVECHO BIOTECHNOLOGY November 2023 3
Slide 4: Company Snapshot
COMPANY SNAPSHOT AVE Corporate Summary1 Board and Management Team - 20+ years Avecho, PhD Biochemistry For personal use only Dr Paul Gavin - Ex-AVE CSO, Inventor of TPM platform Total shares (including T2) 3.17 Bn Chief Executive Officer - Ran pharmaceutical development programs from concept to lice
Slide 5: The Global Cannabis Market Is Already Huge
THE GLOBAL CANNABIS MARKET IS ALREADY HUGE Global Legal Cannabis Market1 For personal use only • Legal use (medicinal or adult) in 30 countries • Valued at $17.8 billion USD in 2021 • 65.0% of the market in North America in 2021 Despite the global value of the • Projected compound annual growth rate
Slide 6: The Problem with Cannabinoids
THE PROBLEM WITH CANNABINOIDS Cannabinoids have very poor oral bioavailability; only Avecho’s TPM increases oral CBD absorption ~6% of ingested cannabinoids are absorbed For personal use only Increasing cannabinoid absorption has become a focus for many laboratories around the world Increasing bioav
Slide 7: Pharmaceutical Cannabidiol Is Valuable
PHARMACEUTICAL CANNABIDIOL IS VALUABLE Only one pharmaceutical CBD product is approved by the FDA (Epidiolex®)1 For personal use only • Epidiolex was developed by GW Pharma • Approved for rare childhood epilepsy conditions2 – rarely prescribed • GW Pharma was acquired for $7.2Bn USD by Jazz Pharma (
Slide 8: Insomnia in Australia – Unique CBD Opportunity
INSOMNIA IN AUSTRALIA – UNIQUE CBD OPPORTUNITY Insomnia can be broadly defined as difficulty initiating or maintaining sleep For personal use only The TGA allows CBD products to be registered as over-the- counter (OTC) medicines1 for indications such as insomnia OTC medicines are available direct fr
Slide 9: Phase III Study Design
PHASE III STUDY DESIGN Based upon study design from FDA approved insomnia medications For personal use only Assessments include; Avecho’s Phase III insomnia trial has been • Daily sleep diary to record nightly sleep. designed to maximise the chance of success. • Sleep questionnaire every two weeks.
Slide 10: Timelines to Interim Analysis - Major Go/No Go
TIMELINES TO INTERIM ANALYSIS - MAJOR GO/NO GO 2023 2024 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec For personal use only Funding Activities Manufacturing Activities Clinical supply Registration batches Stability Phase III Trial Results Database b
Slide 11: Value Drivers
VALUE DRIVERS • Proprietary cannabinoid portfolio differentiated with TPM delivery technology For personal use only • Pivotal Phase III trial for an insomnia indication ready to go • Dosing to commence early 2024 – Interim analysis Q3/Q4 • CBD capsule targeting over-the-counter registration in Austr
Slide 12: Questions Welcome
QUESTIONS WELCOME For personal use only Dr Paul Gavin Chief Executive Officer T. +61 3 9002 5000 E. pgavin@avecho.com.au Melbourne Office Unit A8, 2A Westall Road Hallmarc Business Park Clayton VIC 3168 Questions welcome via Australia our InvestorHub platform. T: +61 3 9002 5000 E: info@avecho.com.a
Avecho Biotechnology — Investor Presentation (November 2023) on 6ix